{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:43:37Z","timestamp":1794577417739,"version":"4.9.1"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.psychres.2021.114231","type":"journal-article","created":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T14:15:38Z","timestamp":1633961738000},"page":"114231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine's mechanisms associated with antidepressant and psychotomimetic effects"],"prefix":"10.1016","volume":"306","author":[{"given":"Tuyen T.","family":"Le","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Di Vincenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla M.","family":"Teopiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yena","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle S.","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanna M.W.","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson B.","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger C.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangguang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Nasri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartej","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orly","family":"Lipsitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehala","family":"Subramaniapillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo B.","family":"Mansur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Rosenblat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psychres.2021.114231_bib0001","doi-asserted-by":"crossref","DOI":"10.3390\/biom10060947","article-title":"Brain NMDA receptors in schizophrenia and depression","volume":"10","author":"Adell","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.psychres.2021.114231_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopsych.2017.06.011","article-title":"Efficacy of esketamine in the treatment of depression with psychotic features: a case series","author":"Ajub","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2021.114231_bib0003","first-page":"251","article-title":"Continuation therapy after ECT for delusional depression: a naturalistic study of prophylactic treatments and relapse","volume":"3","author":"Aronson","year":"1987","journal-title":"Convuls. Ther."},{"key":"10.1016\/j.psychres.2021.114231_bib0004","doi-asserted-by":"crossref","DOI":"10.1111\/j.1471-4159.2006.03913.x","article-title":"The glutamate\/GABA-glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer","author":"Bak","year":"2006","journal-title":"J. Neurochem."},{"key":"10.1016\/j.psychres.2021.114231_bib0005","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-20190-4","article-title":"The role of dissociation in ketamine's antidepressant effects","volume":"11","author":"Ballard","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.psychres.2021.114231_bib0006","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11920-009-0045-6","article-title":"Neuropsychological abnormalities in schizophrenia and major mood disorders: similarities and differences","volume":"11","author":"Barch","year":"2009","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.psychres.2021.114231_bib0007","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.4693","article-title":"Association of ketamine with psychiatric symptoms and implications for its therapeutic use and for understanding schizophrenia: a systematic review and meta-analysis","author":"Beck","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.psychres.2021.114231_bib0008","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0278-5846(03)00080-0","article-title":"Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia","volume":"27","author":"Becker","year":"2003","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2021.114231_bib0009","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1212\/WNL.0b013e3181cc89e3","article-title":"Glutamate transporters: diversity, function, and involvement in neurologic disease","volume":"74","author":"Benarroch","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.psychres.2021.114231_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2018.07.033","article-title":"Cognitive function of patients with treatment-resistant depression after a single low dose of ketamine infusion","volume":"241","author":"Chen","year":"2018","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.psychres.2021.114231_bib0012","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.schres.2018.02.049","article-title":"Similar psychotic and cognitive profile between ketamine dependence with persistent psychosis and schizophrenia","volume":"199","author":"Cheng","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psychres.2021.114231_bib0013","doi-asserted-by":"crossref","DOI":"10.1002\/hup.2475","article-title":"The use of ketamine as an antidepressant: a systematic review and meta-analysis","author":"Coyle","year":"2015","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.114231_bib0014","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/978-3-642-25758-2_10","article-title":"Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications","volume":"213","author":"Coyle","year":"2012","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.psychres.2021.114231_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopsych.2015.05.016","article-title":"The use of ketamine for the treatment of depression in the context of psychotic symptoms: to the editor","author":"da Frota Ribeiro","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2021.114231_bib0016","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","article-title":"Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial","volume":"76","author":"Daly","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.psychres.2021.114231_bib0017","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1093\/schbul\/sbr144","article-title":"Subanaesthetic ketamine treatment alters prefrontal cortex connectivity with thalamus and ascending subcortical systems","volume":"39","author":"Dawson","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psychres.2021.114231_bib0018","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s002130050856","article-title":"Differential effects of ketamine on gating of auditory evoked potentials and prepulse inhibition in rats","volume":"142","author":"De Bruin","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.psychres.2021.114231_bib0019","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1177\/0269881114527361","article-title":"Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic","volume":"28","author":"Diamond","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.114231_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2016.05.007","article-title":"Potential involvement of serotonergic signaling in ketamine's antidepressant actions: a critical review","author":"du Jardin","year":"2016","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2021.114231_bib0021","doi-asserted-by":"crossref","DOI":"10.1038\/nm.4050","article-title":"Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants","author":"Duman","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.psychres.2021.114231_bib0022","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S0140-6736(70)91273-0","article-title":"Ketamine as an induction agent in anaesthetics","volume":"295","author":"Dundee","year":"1970","journal-title":"Lancet"},{"key":"10.1016\/j.psychres.2021.114231_bib0023","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jaac.2017.01.006","article-title":"Ketamine as a treatment for adolescent depression: a case report","volume":"56","author":"Dwyer","year":"2017","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.psychres.2021.114231_bib0024","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.nbd.2012.05.003","article-title":"Subchronic ketamine treatment leads to permanent changes in EEG, cognition and the astrocytic glutamate transporter EAAT2 in mice","volume":"47","author":"Featherstone","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.psychres.2021.114231_bib0025","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","article-title":"Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1)","volume":"22","author":"Fedgchin","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.psychres.2021.114231_bib0026","doi-asserted-by":"crossref","DOI":"10.3109\/07853899608999116","article-title":"The core symptoms of schizophrenia","author":"Flaum","year":"1996","journal-title":"Ann. Med."},{"key":"10.1016\/j.psychres.2021.114231_bib0027","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.tics.2006.02.008","article-title":"Schizophrenia, ketamine and cannabis: evidence of overlapping memory deficits","volume":"10","author":"Fletcher","year":"2006","journal-title":"Trends Cogn. Sci."},{"key":"10.1016\/j.psychres.2021.114231_bib0028","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1001\/jama.2019.10517","article-title":"Effect of continuing olanzapine vs placebo on relapse among patients with psychotic depression in remission: the STOP-PD II randomized clinical trial","volume":"322","author":"Flint","year":"2019","journal-title":"JAMA - J. Am. Med. Assoc."},{"key":"10.1016\/j.psychres.2021.114231_bib0029","doi-asserted-by":"crossref","DOI":"10.1177\/0269881113512909","article-title":"Reviewing the ketamine model for schizophrenia","author":"Frohlich","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.114231_bib0030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1124\/jpet.116.239228","article-title":"Antidepressant potential of (R)-ketamine in rodent models: comparison with (S)-ketamine","volume":"361","author":"Fukumoto","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.psychres.2021.114231_bib0031","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/clipsy.bpi004","article-title":"Cognitive behavior therapies for psychotic disorders: current empirical status and future directions","volume":"12","author":"Gaudiano","year":"2005","journal-title":"Clin. Psychol. Sci. Pract."},{"key":"10.1016\/j.psychres.2021.114231_bib0032","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1159\/000104703","article-title":"The treatment of psychotic major depression: is there a role for adjunctive psychotherapy?","volume":"76","author":"Gaudiano","year":"2007","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.psychres.2021.114231_bib0033","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.neubiorev.2020.11.020","article-title":"The effects of ketamine on cognition in treatment-resistant depression: a systematic review and priority avenues for future research","volume":"120","author":"Gill","year":"2021","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.psychres.2021.114231_bib0034","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2174\/157340006776876003","article-title":"Psychotic (Delusional) major depression in the elderly: a review","volume":"2","author":"Gournellis","year":"2006","journal-title":"Curr. Psychiatry Rev."},{"key":"10.1016\/j.psychres.2021.114231_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2020.112629","article-title":"Ketamine as a mental health treatment: are acute psychoactive effects associated\u00a0 with outcomes? A systematic review","volume":"392","author":"Grabski","year":"2020","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.psychres.2021.114231_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113935","article-title":"Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine","volume":"177","author":"Hashimoto","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.psychres.2021.114231_bib0037","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1192\/apt.bp.114.014274","article-title":"Ketamine as a rapid antidepressant: the debate and implications","volume":"22","author":"Ho","year":"2016","journal-title":"BJPsych Adv."},{"key":"10.1016\/j.psychres.2021.114231_bib0038","doi-asserted-by":"crossref","DOI":"10.1177\/0269881114563634","article-title":"Glutamate and dopamine in schizophrenia: an update for the 21st century","author":"Howes","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.114231_bib0039","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/nyas.12547","article-title":"The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies","volume":"1338","author":"Hu","year":"2015","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.psychres.2021.114231_bib0040","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2014.112","article-title":"Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: a systematic overview of meta-analyses","author":"Huhn","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.psychres.2021.114231_bib0041","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1600-0773.1995.tb01041.x","article-title":"Interaction of the chiral forms of ketamine with opioid, phencyclidine, \u03c3 and muscarinic receptors","volume":"77","author":"Hustveit","year":"1995","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/j.psychres.2021.114231_bib0042","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.neubiorev.2009.07.010","article-title":"Mice with genetically altered glutamate receptors as models of schizophrenia: a comprehensive review","volume":"34","author":"Inta","year":"2010","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.psychres.2021.114231_bib0043","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/0091-3057(91)90571-I","article-title":"Ketamine-induced hyperlocomotion associated with alteration of presynaptic components of dopamine neurons in the nucleus accumbens of mice","volume":"40","author":"Irifune","year":"1991","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.psychres.2021.114231_bib0044","doi-asserted-by":"crossref","DOI":"10.1017\/S0033291717002501","article-title":"Epidemiology of psychotic depression - Systematic review and meta-analysis","author":"J\u00e4\u00e4skel\u00e4inen","year":"2018","journal-title":"Psychol. Med."},{"key":"10.1016\/j.psychres.2021.114231_bib0045","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.biopsych.2015.07.005","article-title":"Abnormal gamma oscillations in N-methyl-d-aspartate receptor hypofunction models of schizophrenia","volume":"79","author":"Jadi","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2021.114231_bib118","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S2215-0366(18)30268-2","article-title":"The relationship between cortical glutamate and striatal dopamine in first-episode psychosis: a cross-sectional multimodal PET and magnetic resonance spectroscopy imaging study","volume":"5","author":"Jauhar","year":"2018","journal-title":"The Lancet Psychiatry"},{"key":"10.1016\/j.psychres.2021.114231_bib0046","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/schbul\/sbs100","article-title":"Twenty-five years of glutamate in schizophrenia: are we there yet?","volume":"38","author":"Javitt","year":"2012","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psychres.2021.114231_bib0047","doi-asserted-by":"crossref","DOI":"10.1177\/0269881117747579","article-title":"Beyond static measures: a review of functional magnetic resonance spectroscopy and its potential to investigate dynamic glutamatergic abnormalities in schizophrenia","author":"Jelen","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.114231_bib0048","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/0269881120959644","article-title":"Ketamine: a tale of two enantiomers","volume":"35","author":"Jelen","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.114231_bib0049","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.neuroscience.2004.03.039","article-title":"Repeated application of ketamine to rats induces changes in the hippocampal expression of parvalbumin, neuronal nitric oxide synthase and cFOS similar to those found in human schizophrenia","volume":"126","author":"Keilhoff","year":"2004","journal-title":"Neuroscience"},{"key":"10.1016\/j.psychres.2021.114231_bib0050","article-title":"A systematic review of therapeutic ketamine use in children and adolescents with treatment-resistant mood disorders","author":"Kim","year":"2020","journal-title":"Eur. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.psychres.2021.114231_bib0051","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1017\/S0033291716000064","article-title":"Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories","volume":"46","author":"Kishimoto","year":"2016","journal-title":"Psychol. Med."},{"key":"10.1016\/j.psychres.2021.114231_bib0052","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00429-011-0351-8","article-title":"Comparison of the effects of acute and chronic administration of ketamine on hippocampal oscillations: relevance for the NMDA receptor hypofunction model of schizophrenia","volume":"217","author":"Kittelberger","year":"2012","journal-title":"Brain Struct. Funct."},{"key":"10.1016\/j.psychres.2021.114231_bib0053","first-page":"236","article-title":"Delusional depression in the elderly: a community study","volume":"22","author":"Kivela","year":"1989","journal-title":"Z. Gerontol."},{"key":"10.1016\/j.psychres.2021.114231_bib0054","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.bbr.2011.05.035","article-title":"Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression","volume":"224","author":"Koike","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.psychres.2021.114231_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2020.112548","article-title":"Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant","volume":"384","author":"Kokane","year":"2020","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.psychres.2021.114231_bib0056","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/mp.2017.190","article-title":"The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders","volume":"23","author":"Kokkinou","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.psychres.2021.114231_bib0057","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses","volume":"51","author":"Krystal","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.psychres.2021.114231_bib0058","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0006-3223(00)01037-4","article-title":"Long-term outcome of patients who receive ketamine during research","volume":"49","author":"Lahti","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2021.114231_bib0059","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0893-133X(01)00243-3","article-title":"Effects of ketamine in normal and schizophrenic volunteers","volume":"25","author":"Lahti","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psychres.2021.114231_bib0060","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jad.2012.07.036","article-title":"The treatment of psychotic depression: is there consensus among guidelines and psychiatrists?","volume":"145","author":"Leadholm","year":"2013","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.psychres.2021.114231_bib0061","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3389\/fnmol.2019.00185","article-title":"NMDAR hypofunction animal models of schizophrenia","volume":"12","author":"Lee","year":"2019","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.psychres.2021.114231_bib0062","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.schres.2011.09.004","article-title":"Relationship of neurocognitive deficits to diagnosis and symptoms across affective and non-affective psychoses","volume":"133","author":"Lewandowski","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psychres.2021.114231_bib0063","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1190287","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.psychres.2021.114231_bib0064","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.biopsych.2010.12.015","article-title":"Glutamate N-methyl-d-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure","volume":"69","author":"Li","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2021.114231_bib0065","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/00952990.2016.1278449","article-title":"Ketamine and international regulations","volume":"43","author":"Liao","year":"2017","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.psychres.2021.114231_bib0066","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2019.08.012","article-title":"Repeated intravenous infusions of ketamine: neurocognition in patients with anxious and nonanxious treatment-resistant depression","volume":"259","author":"Liu","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.psychres.2021.114231_bib0067","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1021\/jm00326a019","article-title":"The synthesis of phencyclidine and other 1-arylcyclohexylamines","volume":"8","author":"Maddox","year":"1965","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.psychres.2021.114231_bib0068","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.neubiorev.2020.07.038","article-title":"The role of norepinephrine in the pathophysiology of schizophrenia","volume":"118","author":"M\u00e4ki-Marttunen","year":"2020","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.psychres.2021.114231_bib0069","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0893-133X(97)00036-5","article-title":"Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics","volume":"17","author":"Malhotra","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psychres.2021.114231_bib0070","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0893-133X(95)00137-3","article-title":"NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers","volume":"14","author":"Malhotra","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psychres.2021.114231_bib0071","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/wps.20693","article-title":"Dopamine and glutamate in schizophrenia: biology, symptoms and treatment","volume":"19","author":"McCutcheon","year":"2020","journal-title":"World Psychiatry"},{"key":"10.1016\/j.psychres.2021.114231_bib0072","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jad.2020.06.050","article-title":"The effect of intravenous, intranasal, and oral ketamine in mood disorders: a meta-analysis","volume":"276","author":"McIntyre","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.psychres.2021.114231_bib0073","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2021.114231_bib0074","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/jamapsychiatry.2016.0442","article-title":"Nature of glutamate alterations in schizophrenia a meta-analysis of proton magnetic resonance spectroscopy studies","volume":"73","author":"Merritt","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.psychres.2021.114231_bib0075","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1001\/archgenpsychiatry.2009.79","article-title":"A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD)","volume":"66","author":"Meyers","year":"2009","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.psychres.2021.114231_bib0076","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00019442-200111000-00010","article-title":"Continuation treatment of delusional depression in older adults","volume":"9","author":"Meyers","year":"2001","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.psychres.2021.114231_bib0077","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s00213-006-0572-3","article-title":"Acute and chronic effects of ketamine upon human memory: a review","volume":"188","author":"Morgan","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.psychres.2021.114231_bib0078","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/npp.2014.298","article-title":"Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial","volume":"40","author":"Murrough","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psychres.2021.114231_bib0079","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00213-013-3255-x","article-title":"Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response","volume":"231","author":"Murrough","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.psychres.2021.114231_bib0080","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00213-010-1834-7","article-title":"Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats","volume":"210","author":"Nemeth","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.psychres.2021.114231_bib0081","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0893-133X(98)00067-0","article-title":"Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis","volume":"20","author":"Newcomer","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psychres.2021.114231_bib0082","article-title":"The role of glutamate transporters in the pathophysiology of neuropsychiatric disorders","volume":"3","author":"O'Donovan","year":"2017","journal-title":"npj Schizophr"},{"key":"10.1016\/j.psychres.2021.114231_bib0083","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1176\/appi.ajp.159.11.1855","article-title":"Prevalence of depressive episodes with psychotic features in the general population","volume":"159","author":"Ohayon","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2021.114231_bib0084","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41380-018-0041-5","article-title":"Synaptic loss in schizophrenia: a meta-analysis and systematic review of synaptic protein and mRNA measures","volume":"24","author":"Osimo","year":"2019","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.psychres.2021.114231_bib0085","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jad.2012.08.040","article-title":"Clinical experience using intranasal ketamine in the treatment of pediatric bipolar disorder\/fear of harm phenotype","volume":"147","author":"Papolos","year":"2013","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.psychres.2021.114231_bib0086","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/j.biopsych.2016.08.041","article-title":"Ketamine and psychosis history: antidepressant efficacy and psychotomimetic effects postinfusion","volume":"82","author":"Pennybaker","year":"2017","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2021.114231_bib0087","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpsychires.2020.03.020","article-title":"Registered clinical trials investigating ketamine for psychiatric disorders","volume":"127","author":"Peyrovian","year":"2020","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.psychres.2021.114231_bib0088","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.pharmthera.2019.02.017","article-title":"Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies","volume":"199","author":"Pham","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.psychres.2021.114231_bib0089","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/mp.2013.136","article-title":"Imaging glutamate in schizophrenia: review of findings and implications for drug discovery","volume":"19","author":"Poels","year":"2014","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.psychres.2021.114231_bib0090","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/schbul\/sbt046","article-title":"Challenges in the treatment of major depressive disorder with psychotic features","volume":"39","author":"Rothschild","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psychres.2021.114231_bib0091","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4062\/biomolther.2012.20.1.001","article-title":"Glutamate receptor abnormalities in schizophrenia: implications for innovative treatments","volume":"20","author":"Rubio","year":"2012","journal-title":"Biomol. Ther. (Seoul)."},{"key":"10.1016\/j.psychres.2021.114231_bib0092","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1001\/jama.285.10.1299","article-title":"Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial","volume":"285","author":"Sackeim","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.psychres.2021.114231_bib0093","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1017\/S1461145714001011","article-title":"Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression","volume":"17","author":"Shiroma","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.psychres.2021.114231_bib0094","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2215-0366(17)30272-9","article-title":"Side-effects associated with ketamine use in depression: a systematic review","volume":"5","author":"Short","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.psychres.2021.114231_bib0095","first-page":"76","article-title":"Ketamine - more mechanisms of action than just NMDA blockade","volume":"4","author":"Sleigh","year":"2014","journal-title":"Trends Anaesth. Crit. Care"},{"key":"10.1016\/j.psychres.2021.114231_bib117","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/mp.2011.171","article-title":"Ketamine effects on brain GABA and glutamate levels with 1H-MRS: Relationship to ketamine-induced psychopathology","volume":"17","author":"Stone","year":"2012","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.psychres.2021.114231_bib0096","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1213\/00000539-198010000-00008","article-title":"Physostigmine antagonizes ketamine","volume":"59","author":"Toro-Matos","year":"1980","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.psychres.2021.114231_bib0097","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/pr.109.002451","article-title":"Glutamate receptor ion channels: structure, regulation, and function","volume":"62","author":"Traynelis","year":"2010","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.psychres.2021.114231_bib0098","unstructured":"U.S. Food and Drug Administration (FDA), 2019. FDA approves new nasal spray medication for treatment-resistant depression; Available Only At A Certified Doctor'S Office Or Clinic. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified. (accessed 10 May 2021)."},{"key":"10.1016\/j.psychres.2021.114231_bib0099","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2020-238135","article-title":"Oral S-ketamine effective after deep brain stimulation in severe treatment-resistant depression and extensive comorbidities","volume":"14","author":"Veraart","year":"2021","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.psychres.2021.114231_bib0100","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1523\/JNEUROSCI.16-01-00373.1996","article-title":"NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine","volume":"16","author":"Verma","year":"1996","journal-title":"J. Neurosci."},{"key":"10.1016\/j.psychres.2021.114231_bib0101","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0924-977X(96)00042-9","article-title":"Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET)","volume":"7","author":"Vollenweider","year":"1997","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.psychres.2021.114231_bib0102","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2020.172870","article-title":"A historical review of antidepressant effects of ketamine and its enantiomers","volume":"190","author":"Wei","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.psychres.2021.114231_bib0103","article-title":"Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor","author":"Wei","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.psychres.2021.114231_bib0104","doi-asserted-by":"crossref","first-page":"463","DOI":"10.4088\/JCP.07m03890yel","article-title":"Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study","volume":"71","author":"Woods","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2021.114231_bib0105","unstructured":"World Health Organization WHO, 2017. Depression and other common mental disorders: global health estimates. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/254610\/WHO-MSD-MER-2017.2-eng.pdf. (accessed 10 May 2020)."},{"key":"10.1016\/j.psychres.2021.114231_bib0106","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jpsychires.2014.12.012","article-title":"Preliminary analysis of positive and negative syndrome scale in ketamine-associated psychosis in comparison with schizophrenia","volume":"61","author":"Xu","year":"2015","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.psychres.2021.114231_bib0107","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyv124","article-title":"Effects of low-dose and very low-dose ketamine among patients with major depression: a systematic review and meta-analysis","volume":"19","author":"Xu","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.psychres.2021.114231_bib0108","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1007\/s00213-014-3543-0","article-title":"Rapid antidepressant effects and abuse liability of ketamine","volume":"231","author":"Yang","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.psychres.2021.114231_bib0109","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.biopsych.2017.05.016","article-title":"Mechanistic target of rapamycin\u2013independent antidepressant effects of (R)-ketamine in a social defeat stress model","volume":"83","author":"Yang","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2021.114231_bib0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/tp.2015.136","article-title":"R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects","volume":"5","author":"Yang","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.psychres.2021.114231_bib0111","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41398-019-0624-1","article-title":"Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites","volume":"9","author":"Yang","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.psychres.2021.114231_bib0112","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/mp.2017.255","article-title":"Mechanisms of ketamine action as an antidepressant","volume":"23","author":"Zanos","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.psychres.2021.114231_bib0113","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.117.015198","article-title":"Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms","volume":"70","author":"Zanos","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.psychres.2021.114231_bib0114","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1089\/cap.2019.0028","article-title":"Successful use of ketamine for the treatment of psychotic depression in a teenager","volume":"29","author":"Zarrinnegar","year":"2019","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.114231_bib0115","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.pbb.2013.11.033","article-title":"R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine","volume":"116","author":"Zhang","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.psychres.2021.114231_bib0116","doi-asserted-by":"crossref","first-page":"11158","DOI":"10.1523\/JNEUROSCI.1547-16.2016","article-title":"Ketamine: NMDA receptors and beyond","volume":"36","author":"Zorumski","year":"2016","journal-title":"J. Neurosci."}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178121005278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178121005278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T05:51:31Z","timestamp":1759038691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178121005278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":117,"alternative-id":["S0165178121005278"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2021.114231","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine's mechanisms associated with antidepressant and psychotomimetic effects","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2021.114231","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114231"}}